Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesHematology/Oncologyquartz trastuzumab coverage Prior Auth | OpenPayer
    Ask Trek AI about this page
    CurrentquartzPolicy N/A

    Trastuzumab products (intravenous) — Clinical coverage and authorization criteria

    Customize your policy alerts

    Sign up for all quartz policy alerts

    Know when quartz releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Clinical coverage and authorization guidance for trastuzumab and its biosimilars for HER2-positive malignancies for Quartz members; includes FDA-approved and supported off-label uses and dosing summaries.

    Policy Summary
    Payerquartz
    PolicyTrastuzumab products (intravenous) — Clinical coverage and authorization criteria
    Policy CodePolicy N/A
    Change TypeNo material clinical or coverage changes
    Effective DateDec 18, 2024
    Last ReviewDec 18, 2024
    Next Review DateDec 18, 2024
    Key ActionObtain prior authorization when required and document HER2-positive status using an FDA-approved companion diagnostic; Kanjinti and Trazimera are available without prior authorization.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    7trastuzumab products listed
    52 weeksadjuvant treatment duration
    ≥18minimum age
    2024-12-18last review

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    10references

    Recommended Authorization Criteria

    Breast Cancer (FDA-approved)

    Covered when ALL of the following are met for breast cancer (FDA-approved indications):

    Breast cancer (FDA-approved): a. Patient is >= 18 years of age; AND b. Patient has HER2-positive disease; AND c. Patient meets ONE of the following: (i) Trastuzumab is used for neoadjuvant (preoperative)/adjuvant therapy; OR (ii) Trastuzumab is used for recurrent or metastatic disease; AND d. The medication is prescribed by or in consultation with an oncologist.

    Gastric/Esophageal/GE-junction Cancer (FDA-approved)

    Covered when ALL of the following are met for gastric/esophageal/GE-junction cancer (FDA-approved):

    Gastric/GEJ cancer (FDA-approved): a. Patient is >= 18 years of age; AND b. Patient has locally advanced or metastatic disease; AND c. Patient has HER2-positive disease; AND d. Patient meets BOTH of the following: (i) Trastuzumab will be used as first-line therapy; AND (ii) Trastuzumab will be used in combination with chemotherapy; AND e. The medication is prescribed by or in consultation with an oncologist.

    Colon/Rectal Cancer (supportive evidence)

    Covered when ALL of the following are met for colon or rectal cancer (supportive evidence):

    Colon/Rectal cancer (supportive): a. Patient is >= 18 years of age; AND b. Patient has advanced or metastatic disease; AND c. Patient has HER2-positive disease; AND d. The medication is used in combination with pertuzumab (Perjeta), lapatinib, or tucatinib (Tukysa); AND e. The medication is prescribed by or in consultation with an oncologist.

    Dosing: various regimens including 8 mg/kg IV load then 6 mg/kg IV q3w or 4 mg/kg IV load then 2 mg/kg IV weekly (per source).

    Biliary Tract Cancer (supportive evidence)

    Covered when ALL of the following are met for biliary tract cancer (supportive evidence):

    Biliary tract cancer (supportive): a. Patient is >= 18 years of age; AND b. Patient has unresectable or metastatic disease; AND c. Patient has HER2-positive disease; AND d. The medication will be used in combination with pertuzumab (Perjeta) or tucatinib (Tukysa); AND e. The patient has tried one systemic regimen; AND f. The medication is prescribed by or in consultation with an oncologist.

    Dosing: 8 mg/kg IV load followed by 6 mg/kg IV not more frequently than once every 3 weeks (per source).

    Endometrial Carcinoma (supportive evidence)

    Covered when ALL of the following are met for endometrial carcinoma (supportive evidence):

    Endometrial carcinoma (supportive): a. Patient is >= 18 years of age; AND b. Patient has advanced or recurrent uterine serous carcinoma; AND c. Patient has HER2-positive disease; AND d. Trastuzumab will be used in combination with chemotherapy; AND e. The medication is prescribed by or in consultation with an oncologist.

    Dosing: 8 mg/kg IV load followed by 6 mg/kg IV q3w (per source).

    Salivary Gland Tumor (supportive evidence)

    Covered when ALL of the following are met for salivary gland tumors (supportive evidence):

    Salivary gland tumor (supportive): a. Patient is >= 18 years of age; AND b. Patient has recurrent, unresectable, or metastatic disease; AND c. Patient has HER2-positive disease; AND d. The medication is prescribed by or in consultation with an oncologist.

    Dosing: 8 mg/kg IV load followed by 6 mg/kg IV q3w (per source).

    Coverage is not recommended for circumstances not listed in the Recommended Authorization Criteria. Criteria will be updated as new published data are available.

    Circumstances not listed in the Recommended Authorization Criteria are not recommended for approval. Requests outside the specified criteria should be expected to be denied unless and until the policy is amended based on new evidence.

    Provider Requirements and Authorization Notes

    Prior Authorization

    Prior authorization required for most trastuzumab products

    Most trastuzumab products require prior authorization with Quartz; Kanjinti and Trazimera are available without prior authorization.

    Prior Authorization

    Authorization requires meeting Recommended Authorization Criteria

    Authorization is recommended only when the request meets the policy's Recommended Authorization Criteria; requests outside those criteria are not recommended for approval.

    Step Therapy

    Biliary tract cancer: required sequencing and combination

    For biliary tract cancer, trastuzumab is supported only when used in combination with pertuzumab (Perjeta) or tucatinib (Tukysa) after the patient has tried one systemic regimen.

    Clinical Background

    Trastuzumab is a monoclonal antibody that targets the human epidermal growth factor receptor 2 (HER2) and is indicated for HER2-overexpressing breast cancer in adjuvant and metastatic settings and for metastatic gastric or gastroesophageal junction adenocarcinoma in combination with chemotherapy. Biosimilar trastuzumab products share the FDA-approved indications of the originator. Clinical guidelines (NCCN) also support trastuzumab use across multiple HER2-driven tumor types including select colorectal, biliary tract, endometrial (uterine serous), and salivary gland tumors where supporting evidence exists.

    Terms and References

    inv-18: HER2-positive — definition
    DefinitionTumors that overexpress or have amplification of the human epidermal growth factor receptor 2 (HER2/neu), identified using an FDA-approved companion diagnostic.
    Test specificitySelection for therapy must be based on an FDA-approved companion diagnostic specific for breast cancer or gastric cancer.
    Minimum ageApplies to patients ≥ 18 years of age in all listed indications.
    Clinical implicationHER2-positive status is required for covered use of trastuzumab and its biosimilars across indicated tumor types.
    inv-19: Herceptin prescribing information
    Product referenceHerceptin intravenous infusion prescribing information (Genentech); Herceptin prescribing information cited as reference 1.

    Indication by Line of Therapy

    first-line

    First-line: Trastuzumab will be used as first-line therapy in combination with chemotherapy for metastatic or locally advanced disease (gastric/GEJ indication).

    This reflects the line-of-therapy requirement in the gastric/GEJ FDA-approved criteria.

    salvage

    Salvage: Trastuzumab will be used in combination with pertuzumab (Perjeta) or tucatinib (Tukysa) as subsequent-line/salvage therapy after the patient has tried one systemic regimen for unresectable or metastatic HER2-positive biliary tract disease.

    Per source, patient must have tried one systemic regimen prior to use.

    Diagnostic Test Requirements

    inv-23: HER2 — biomarker requirement
    DefinitionHER2-positive per an FDA-approved companion diagnostic (test specific for breast cancer or gastric cancer).
    Selection requirementFor all indications, patients must be selected for therapy based on an FDA-approved companion diagnostic for trastuzumab.
    Test scopeCompanion diagnostics are specific for breast cancer or gastric cancer per product labeling.
    Therapeutic relevanceHER2 positivity is required for covered use of trastuzumab and its biosimilars across FDA-approved indications.

    Dosing and Administration

    IndicationDosing regimen
    Adjuvant breast cancer (total 52 weeks)Initial 4 mg/kg IV, then 2 mg/kg IV weekly for 12 weeks (with paclitaxel or docetaxel) or 18 weeks (with docetaxel/carboplatin); one week after last weekly dose give 6 mg/kg IV every 3 weeks to complete 52 weeks. Alternative: initial 8 mg/kg IV then 6 mg/kg IV every 3 weeks for a total of 52 weeks. Extending beyond 1 year not recommended.
    Metastatic breast cancerInitial 4 mg/kg IV followed by 2 mg/kg IV weekly (trastuzumab alone or with paclitaxel) until disease progression.
    Metastatic or locally advanced gastric/esophageal/GE‑junction cancer (first‑line, with chemotherapy)Initial 8 mg/kg IV followed by 6 mg/kg IV every 3 weeks until progression. Guidelines also list alternative schedules (e.g., 6 mg/kg IV Day 1 then 4 mg/kg IV every 14 days) for first‑ or second‑line therapy in combination with chemotherapy.
    Alternate trastuzumab regimens (other tumor types / combinations)Other approved/used schedules include: 4 mg/kg IV then 2 mg/kg IV weekly (not more frequently than once weekly); 8 mg/kg IV then 6 mg/kg IV every 3 weeks (not more frequently than once every 3 weeks); and 6 mg/kg IV then 4 mg/kg IV every 2 weeks. Alternate dosing assessed case‑by‑case.
    Policy Summary
    Payerquartz
    PolicyTrastuzumab products (intravenous) — Clinical coverage and authorization criteria
    Policy CodePolicy N/A
    Change TypeNo material clinical or coverage changes
    Effective DateDec 18, 2024
    Last ReviewDec 18, 2024
    Next Review DateDec 18, 2024
    Key ActionObtain prior authorization when required and document HER2-positive status using an FDA-approved companion diagnostic; Kanjinti and Trazimera are available without prior authorization.
    SourceLink
    On This Page
    Recommended Authorization CriteriaProvider Requirements and Authorization NotesClinical BackgroundTerms and ReferencesIndication by Line of TherapyDiagnostic Test RequirementsDosing and Administration
    • Medication will be used in combination with Perjeta (pertuzumab) or Tukysa (tucatinib).
    • Patient must have tried one systemic regimen prior to use.
    Note
    Documentation Required

    Required diagnostic test and specialist prescriber

    Selection for therapy must be based on an FDA‑approved companion diagnostic specific for breast or gastric cancer, and the medication should be prescribed by or in consultation with an oncologist.

    • Tests are specific for breast cancer or gastric cancer.
    • Medication prescribed by or in consultation with an oncologist is required.
    Note

    Supporting references for clinical context

    Product prescribing information (Herceptin intravenous infusion) and NCCN guideline versions are cited to support clinical review and authority for indications.

    • Herceptin intravenous infusion prescribing information (Genentech; February 2021).
    • NCCN Breast Cancer Clinical Practice Guidelines in Oncology (version 4.2024).
    Denial Risk

    Non‑listed indications are not recommended for approval

    Coverage is not recommended for circumstances not listed in the Recommended Authorization Criteria.

    Denial Risk

    Denial risk for non‑listed indications

    Requests for indications or uses outside the Recommended Authorization Criteria carry a denial risk because coverage is not recommended for circumstances not listed in the criteria.

    UsePrescribing information provides FDA-approved indications and dosing for trastuzumab (Herceptin).
    Publication dateHerceptin prescribing information referenced: February 2021 (per document).
    inv-20: NCCN guideline references
    Primary guidelinesNCCN Clinical Practice Guidelines referenced for breast, gastric, colon, rectal, biliary tract, uterine, and head & neck cancers (multiple versions cited).
    Versions citedNCCN Breast v4.2024; Gastric v2.2024; Colon v4.2024; Rectal v3.2024; Biliary Tract v3.2024; Uterine v2.2024; Head & Neck v4.2024.
    CompendiumNCCN Drugs & Biologics Compendium (search term: trastuzumab) cited to support indications and regimen selections.